T1	Participants 819 945	postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment.
T2	Participants 1025 1120	319 (74.5%) patients in the fulvestrant group and 322 (76.1%) patients in the anastrozole group
T3	Participants 1781 1833	postmenopausal women with advanced breast carcinoma.
